CRISPR Therapeutics AG (CRSP)
60.83
+3.76
(+6.58%)
USD |
NASDAQ |
Aug 25, 16:00
60.51
-0.32
(-0.53%)
After-Hours: 18:33
CRISPR Therapeutics Debt to Equity Ratio : 0.4487 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.4487 |
| March 31, 2026 | 0.4341 |
| December 31, 2025 | 0.1076 |
| September 30, 2025 | 0.1101 |
| June 30, 2025 | 0.1259 |
| March 31, 2025 | 0.1199 |
| December 31, 2024 | 0.1158 |
| September 30, 2024 | 0.1173 |
| June 30, 2024 | 0.1168 |
| March 31, 2024 | 0.1127 |
| December 31, 2023 | 0.1267 |
| September 30, 2023 | 0.1398 |
| June 30, 2023 | 0.135 |
| March 31, 2023 | 0.1295 |
| December 31, 2022 | 0.1301 |
| September 30, 2022 | 0.1239 |
| June 30, 2022 | 0.1159 |
| March 31, 2022 | 0.1065 |
| December 31, 2021 | 0.0938 |
| September 30, 2021 | 0.0817 |
| June 30, 2021 | 0.0734 |
| Date | Value |
|---|---|
| March 31, 2021 | 0.034 |
| December 31, 2020 | 0.0369 |
| September 30, 2020 | 0.0366 |
| June 30, 2020 | 0.0551 |
| March 31, 2020 | 0.058 |
| December 31, 2019 | 0.0559 |
| September 30, 2019 | 0.0703 |
| June 30, 2019 | 0.1144 |
| March 31, 2019 | 0.0964 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Vertex Pharmaceuticals, Inc. | 0.0977 |
| BeOne Medicines Ltd. | 0.3961 |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 0.1166 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.651B |
| Total Liabilities (Quarterly) | 904.22M |
| Shareholders Equity (Quarterly) | 1.747B |
| Current Ratio | 17.85 |
| Net Debt Paydown Yield | -2.14% |